2-AMINO-1,3,4-THIADIAZOLE DERIVATIVES AS POTENTIAL ANTI-HELICOBACTER PYLORI AGENTS – AT A GLANCE

GEORGETA ŞERBAN¹*, IRINA KACSO²

¹University of Oradea, Faculty of Medicine and Pharmacy, Pharmaceutical Chemistry Department, 29 Nicolae Jiga Street, 410028, Oradea, Romania
²National Institute for Research and Development of Isotopic and Molecular Technologies, Department of Biomolecular and Molecular Physics, 67-103 Donath Street, 400293, Cluj-Napoca, Romania

*corresponding author: getaserban_2000@yahoo.com

Abstract

Helicobacter pylori is a major human pathogen that causes gastric and extra-gastric complications and infects around 50% of the global population. Gastric cancer is a serious consequence of H. pylori infection. About 89% of all gastric cancers can be attributed to this pathogen. Treatment is indicated for all infected patients, as a strategy to knock down the risk of gastric malignancy. Due to the high level of antimicrobial resistance, new medicines are needed to treat H. pylori infection. This paper presents 2-amino-1,3,4-thiadiazole derivatives which exhibited anti-H. pylori effect. Some of the reported compounds showed higher activity compared to standard drugs, making the 2-amino-1,3,4-thiadiazole core a possible pattern for future anti-H. pylori agents.

Keywords: Helicobacter pylori, 2-amino-1,3,4-thiadiazole, antimicrobial resistance, anti-H. pylori activity, inhibitory concentration

Introduction

Helicobacter pylori is a Gram-negative spiral-shaped, microaerophilic microorganism identified in 1982 in human gastric mucosa. Gastric colonization with H. pylori can lead to gastrointestinal tract disorders such as chronic active gastritis, gastric and duodenal ulcers, indigestion and malignancies such as gastric mucosa-associated lymphoid tissue (MALT) B-cell lymphoma and gastric adenocarcinoma [1, 3, 16, 21]. In addition, H. pylori infection can lead to systemic complications: idiopathic thrombocytopenic purpura, iron-deficiency anaemia, vitamin B12 deficiency, coronary artery and neurodegenerative diseases, as well as gall bladder disorders (e.g., cholecystitis and cholelithiasis) [3, 6, 38]. The prevalence of H. pylori infection differs from country to country. Inadequate hygiene conditions and the level of development of the country are considered to be risk factors for H. pylori infection and therefore this infection is a feature of the socio-economic and health status of a community [3, 44]. Recent studies have shown an overall prevalence of 44.3% for H. pylori infection worldwide, with a higher prevalence in developing countries, where 50.8% of the population is H. pylori positive, compared to industrialized countries where the prevalence of infection is less than 40% (34.7%). The highest prevalence was observed in Nigeria (89.7%), while the lowest rate was recorded in Yemen (8.9%). In Europe, the highest infection rate was found in Serbia (88.3%) and the lowest in Belgium (11.0%) [44]. Helicobacter species are well adapted to the highly acidic (pH < 2) inhospitable gastric environment and this makes H. pylori one of the most successful human pathogens. Latrogenic transmission through the endoscope is possible, but person-to-person contact is the most accepted transmission route [3, 6, 40].

H. pylori infection and gastrointestinal tract malignancy

One of the most serious consequences of H. pylori infection is gastric cancer, and statistics show that about 89% of all gastric cancers can be attributed to it [11]. Although the mechanism is not clearly understood, H. pylori infection is an important risk factor for gastric malignancy development [1, 38]. Therefore in

FARMACIA, 2020, Vol. 68, 5

https://doi.org/10.31925/farmacia.2020.5.3

785
Current pharmacotherapy for \textit{H. pylori} infection

Treatment of \textit{H. pylori} infection comprises antibacterial agents such as macrolides (clarithromycin, azithromycin) and beta-lactam antibiotics (amoxicillin), nitroimidazoles (metronidazole, tinidazole), fluoroquinolones (levofloxacin, ciprofloxacin), tetracycline, rifabutin or furazolidone. In addition, \textit{H. pylori} appears to be very susceptible to bismuth compounds both in vivo and in vitro. In infected patients, triple or quadruple therapies combining antibiotics, proton pump inhibitors and bismuth compounds have resulted in \textit{H. pylori} eradication rates of over 80% [6]. According to the American College of Gastroenterology (ACG), clarithromycin-based triple therapy that combines clarithromycin with amoxicillin and a proton-pump inhibitor (14 days) is the first-line treatment recommended for the areas where the level of clarithromycin resistance is low, followed by bismuth-based quadruple therapy consisting of bismuth, tetracycline, metronidazole and a proton-pump inhibitor (10 - 14 days). There is no significant difference between these two therapies in terms of the percentage of patients in whom \textit{H. pylori} was eradicated [5, 6]. When the first two therapies fail, one of the following five recommended treatment regimens could be used: concomitant therapy (clarithromycin, amoxicillin, metronidazole and a proton-pump inhibitor for 10 - 14 days), sequential therapy (amoxicillin and a proton-pump inhibitor for 7 days, then clarithromycin, metronidazole and a proton-pump inhibitor for 7 days), hybrid therapy (amoxicillin and a proton-pump inhibitor for 7 days, then amoxicillin, clarithromycin, metronidazole and a proton-pump inhibitor for 7 days), levofloxacin-based triple therapy (levofloxacin, amoxicillin and a proton-pump inhibitor for 10 - 14 days) or fluoroquinolone-based sequential therapy (amoxicillin and a proton-pump inhibitor for 5 - 7 days, then levofloxacin, metronidazole and a proton-pump inhibitor for 5 - 7 days) [5, 6]. However, due to resistant \textit{H. pylori} strains, there is a negative trend of efficacy and 20 - 30% of treatments have failed in recent years. New drugs were added to existing therapy regimens. Addition of rebamipide, a mucoprotective agent that induces prostaglandin synthesis in the gastric mucosa, to antimicrobial regimens gave promising results [2]. Dual therapy with vonoprazan, a new potassium competitive acid blocker and amoxicillin has led to an eradication of over 90% and could become an alternative treatment for \textit{H. pylori} infection [35].

2-Amino-1,3,4-thiadiazole derivatives and the anti-\textit{H. pylori} effect

Azaheterocycles are widely present in naturally occurring organic compounds (e.g., atropine, codeine, morphine, quinine, rutacarpine, toddaquinoline, etc.) as well as in synthetic and pharmaceutical products that exhibit outstanding biological activities [8, 12, 26, 28, 32, 37, 39]. Azithromycin, amoxicillin, metronidazole, tinidazole, levofloxacin, ciprofloxacin, rifabutin and furazolidone used for the therapy of \textit{H. pylori} infection are molecule drugs containing a nitrogen-heterocycle [19, 33, 34, 42]. The thiadiazole ring is a nitrogen-sulphur five membered heterocycle that can be found as a structural unit in biologically active compounds or can be used as a valuable intermediate in the synthesis of organic compounds [29]. Thiadiazole derivatives have been studied as bioactive compounds with medical potential, fungicides and herbicides for agriculture, as well as corrosion inhibitors or chelating agents for industrial purposes [17, 27, 32]. Among the four isomeric forms of the thiadiazole ring (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole and 1,3,4-thiadiazole), the derivatives of 1,3,4-thiadiazole have been the most studied, probably due to the multiple biological effects that these compounds exhibit [17, 27, 29]. The 1,3,4-thiadiazole ring possesses valuable properties, such as high aromaticity associated with good in vivo stability and low toxicity for vertebrates, including humans. The increased lipophilicity due to the sulphur atom and the ability of 1,3,4-thiadiazole derivatives to make mesoionic systems allow these compounds to cross cell membranes, providing enhanced oral bioavailability. Moreover, mesoionic systems enable these derivatives to bind strongly to biomolecules (e.g., DNA, proteins), and therefore to show various biological effects [15, 17, 24, 27, 29, 43]. Indeed, the 1,3,4-thiadiazole ring has proven biological potential, as it can be found in commercially available drugs: acetzolamide and metazolamidine as carbonic anhydrase inhibitors, cefazolin, cefadroxil and sulfamethizole as antibacterial drugs and megazol – an antitrypanosomal agent [7, 10, 27, 29]. In addition, 2-amino-1,3,4-thiadiazole derivatives with antitumour and uricogenic potential have been reported [7, 13, 18, 43]. We already presented some 2-amino-1,3,4-thiadiazoles with antimicrobial [25, 29], anti-leishmanial [27], antitrypanosomal, antimalarial, antitoxoplasmosis [30] and antiviral activities [31]. This mini-review describes 2-amino-1,3,4-thiadiazole derivatives that exhibit anti-\textit{H. pylori} activity.

Nitroheterocyclic derivatives such as nitrofurans (e.g., nitifurimox, nitrofurazide, furazolidone, nitafuratel) and nitromidazoles (e.g., metronidazole, tinidazole) are used in the treatment of protozoan and bacterial infections. Usually metronidazole is the first option. However, tinidazole or furazolidone have also been used for the treatment of \textit{H. pylori} infection [21]. Considering the antimicrobial properties of the above pharmacophores, Foroumadi et al. [9] synthesized some 2-amino-5-(5-nitro-2-heteroaryl)-1,3,4-thia diazoles such as 1-3 belonging to nitrofuran, nitrothiophene and nitroimidazole series. The antimicrobial activity...
was determined through the paper disk diffusion method, by measuring the capability of the studied substances to inhibit the growth of *H. pylori* cultures (sensitive to metronidazole and resistant to metronidazole, respectively). The first evaluation was performed with 1,3,4-thiadiazole at three concentrations: 8, 16 and 32 μg/disk. The results showed a very strong growth inhibition for all three derivatives at 8 μg/disk against both types *H. pylori* strains (inhibition zone > 30 mm) compared to metronidazole as a standard (8 μg/disk, inhibition zone of 18 mm and 11 mm, respectively) (Table I) [9].

Supplementary tests were done against 20 *H. pylori* strains isolated from patients, using the thiadiazole derivatives at concentrations of 32, 16, 8, 4, 2, 1 and 0.5 μg/disk. Except the concentration of 0.5 μg/disk when the compounds had only moderate activity (average of inhibition zone > 12 mm), high activity was shown for all derivatives at concentrations of 1 - 32 μg/disk. At concentration of 8μg/disk, all derivatives exhibited an inhibition zone with an average over 30 mm. This might suggest an activity superior to metronidazole (inhibition zone of 16.3 mm). Among the three tested compounds, the nitrofuran 1 and the nitrotetrahydrophen 2 were the most potent derivatives with equal inhibitory activity at higher concentrations and averages of inhibition zone more than 38 mm (Table II). As demonstrated for other compounds with antimicrobial activity, structure-activity relationship (SAR) studies have shown that the 5-nitro group is indispensable for the biological profile. Moreover, the anti-*H pylori* activity depends on the type of heterocycle at C-5 of the 2-amino-1,3,4-thiadiazole fragment [9].

### Table I

| Inhibition zone (mm) | Metronidazole-sensitive strain | Metronidazole-resistant strain |
|----------------------|--------------------------------|--------------------------------|
|                      | 8 μg/disk | 16 μg/disk | 32 μg/disk | 8 μg/disk | 16 μg/disk | 32 μg/disk |
| 1                    | 35        | 45         | 57         | 37        | 45         | 52         |
| 2                    | 35        | 44         | 59         | 34        | 43         | 55         |
| 3                    | 34        | 43         | 55         | 32        | 41         | 49         |

### Table II

| Average of inhibition zone diameter (mm) |
|-----------------------------------------|
| 0.5 μg/disk | 1 μg/disk | 2 μg/disk | 4 μg/disk | 8 μg/disk | 16 μg/disk | 32 μg/disk |
| 1          | 14.2      | 20.6      | 26.6      | 32.3      | 38.4       | 44.1       | 48.0       |
| 2          | 13.3      | 19.7      | 25.3      | 31.1      | 38.2       | 43.0       | 47.9       |
| 3          | 12.2      | 18.3      | 23.7      | 29.2      | 32.8       | 36.7       | 42.3       |

2-Amino-1,3,4-thiadiazole derivatives having an attached nitroimidazol moiety were prepared by Tafti *et al.* [36]. After evaluating their activity, SAR studies revealed that substitution of the C-2 amine group with alkyl moieties (e.g., methyl, ethyl, butyl, cyclohexyl) results in compounds lacking anti-*H. pylori* activity. The derivative 4 bearing a 4-methylphenyl group exhibited a potent anti-*H. pylori* activity. The biological tests performed at three concentrations (8, 16 and 32 μg/disk) showed moderate to strong activity (inhibition zone diameter of 19, 23 and 25 mm, respectively) against metronidazole-sensitive *H. pylori* strains with respect to standard drug, metronidazole (8 μg/disk, inhibition zone diameter of 18 mm). The compound 4 was also very active against metronidazole-resistant *H. pylori* strains at every concentration (inhibition zone diameter of 21, 26 and 33 mm for 8, 16 and 32 μg/disk, respectively) compared to metronidazole (8 μg/disk, 11 mm). Although the nitro group typically increases antimicrobial activity, the nitro derivative 5 showed only moderate activity against both metronidazole-sensitive (16 mm diameter area) and metronidazole-resistant *H. pylori* strains (14 mm diameter area) at high concentration of 32 μg/disk [36].
Hydrolysis can also play a role in the survival of *H. pylori* in the stomach [4]. Urease is also liable for the development of renal diseases such as urolithiasis, pyelonephritis as well as hepatic encephalopathy, hepatic coma and catheter complications. Control of urease activity through the use of blocking agents could prevent these pathologies [20, 22]. The urease inhibitors can block the enzyme and recently much attention has been paid to the search of urease inhibitors as a new therapy for urease mediated diseases. In this regard some 2,5-disubstituted-1,3,4-thiadiazoles, such as 6-13, have been tested as urease inhibitors in search of a skeleton where structural variations could lead to promising agents. Among the synthesized compounds, the chlorosubstituted derivatives 7 and 11 with chlorine in *ortho* and *para* position of the phenyl group were the most active with the half maximal inhibitory concentration IC₅₀ values of 313.2 μM (82.8% inhibition) and 214.7 μM (91.1% inhibition), respectively. The compound 9 showed a moderate activity (73.4% inhibition) indicating that a *meta*-nitro group on the aryl ring is favourable to biological activity (Table III). It seems that 2,6-dimethyl substituents of the aryl-amino moiety are better matched to the active site of the enzyme, leading to a good inhibition of urease. Thiourea was used as the standard drug [14].

Table III

| R       | R'      | Inhib (%) | IC₅₀ (μM) |
|---------|---------|-----------|-----------|
| 6       | 4-CH₃   | 2.6-(CH₃)₂| 27.1      |
| 7       | 2-Cl    | 2.6-(CH₃)₂| 82.8      | 313.2 ± 0.09 |
| 8       | 4-Cl    | 2.3-(CH₃)₂| 52.8      | 483.55 ± 1.99 |
| 9       | 3-NO₂   | 2.4-(CH₃)₂| 73.4      | 398.2 ± 0.40 |
| 10      | H       | 2.3-(CH₃)₂| 56.8      | 426.1 ± 0.00 |
| 11      | 4-Cl    | 2.6-(CH₃)₂| 91.1      | 214.7 ± 10.16 |
| 12      | 3-Cl    | 2.4-(CH₃)₂| 12.4      | —           |
| 13      | 4-NO₂   | 2.4-(CH₃)₂| 7.2       | —           |

2-Amino-1,3,4-thiadiazole derivative 14 containing pyridine and morpholine nuclei exhibited good urease inhibitory activity with IC₅₀ value of 6.05 ± 1.19 μM. The biological activity was increased at higher concentrations. The results indicate that this structure could be a promising scaffold for future urease inhibitors [4].

2,5-Disubstituted-1,3,4-thiadiazole derivatives 15-20 synthesized by Saleem et al. were evaluated for their urease inhibition activity [22]. Among the studied compounds, the derivative 16 proved to be the most active with IC₅₀ value of 1.55 μM compared to thiourea as standard drug (IC₅₀ value of 26 ± 5 μM). Other compounds showed moderate to good activity with IC₅₀ values ranging from 5.51 μM to 15 μM.
SAR studies showed that inhibitory activity depends on the nature and position of the substituents on the phenyl rings. The most active compound has a 3-methoxybenzyl group and a 2-methoxyphenylamino group as substituents of 1,3,4-thiadiazole ring (IC$_{50}$ value of 1.55 ± 0.16 μM). Changing the 3-methoxybenzyl substituent with the 3-methoxyphenethyl, the urease inhibition activity was reduced (derivative 17, IC$_{50}$ value of 15 ± 4 μM). Decreased inhibitory activity was also recorded for the molecules with many methoxygroups (e.g., derivative 18, IC$_{50}$ value of 10 ± 3 μM) (Table IV) [22].

Metal complexes have also been investigated as urease inhibitors. Zhu et al. [45] designed two zinc (II) complexes, 23 and 24, with general formulae ZnCl$_2$L$_2$, derived from the 2-amino-1,3,4-thiadiazoles 21 (L1) and 22 (L2) as ligands. The X-ray diffraction studies showed that zinc atom has a tetrahedral geometry being coordinated by two nitrogen atoms of the ligand and two chlorine atoms from ZnCl$_2$. Studies of inhibitory activities performed for ligands 21 and 22, as well as metal complexes 23 and 24 at a concentration of 100 μg/mL showed that, compared to acetohydroxamic acid as a reference (92.34% inhibition), ligand 21 is a weak urease-inhibitor (4.30% inhibition), whereas ligand 22 did not inhibit urease at all. Increased activity was observed for complexes 23 and 24, with inhibition values of 14.31% and 17.8%, respectively, suggesting that metal complexes may enhance biological activity and this strategy can be used for the development of new enzyme inhibitors [45].

| R   | R'  | n  | IC$_{50}$ (μM) |
|-----|-----|----|---------------|
| 15  | 3-OCH$_3$ | 4-OCH$_3$ | 2 | 5.51 ± 1.20 |
| 16  | 3-OCH$_3$ | 2-OCH$_3$ | 1 | 1.55 ± 0.16 |
| 17  | 3-OCH$_3$ | 2-OCH$_3$ | 2 | 15 ± 4 |
| 18  | 3,4,5-(OCH$_3$)$_3$ | 3-OCH$_3$ | 2 | 10 ± 3 |
| 19  | 3-OCH$_3$ | 4-Cl  | 1  | —           |
| 20  | 3-OCH$_3$ | 4-Cl  | 2  | —           |

Table IV
Structural details and urease inhibition activity of derivatives 15-20 [22]

![Figure 3](image_url)
The chemical structures of ligands 21-22 and thiazole-zinc (II) complexes 23-24

**Conclusions**

*H. pylori* is a very common human pathogen worldwide that causes a variety of disorders, from gastric and extra-gastric to very serious diseases such as malignancies. Unfortunately, *H. pylori* resistance to antimicrobial drugs is currently a global problem, and the development of resistance is associated with an increased treatment failure rate. In this regard, finding new molecules and/or developing an anti-*H. pylori* vaccine capable of providing an acceptable eradication rate and reduced side effects would be a great advantage. Some 2-amino-1,3,4-thiadiazoles have shown promising anti-*H. pylori* effect. Additional synthetic and clinical experiments are needed to investigate the potential of
2-amino-1,3,4-thiadiazole scaffold and to develop effective healing methodologies for patients infected with *H. pylori*.

Conflict of interest
The authors declare no conflict of interest.

References
1. Andre AR, Pitombeira Ferreira MV, SalaniMota RM, Camargo Ferrari A, Moura Campos Pardini MI, Barem Rabenhorst SH, Gastric adenocarcinoma and *Helicobacter pylori*: correlation with p53 mutation and p27 immuno-expression. *Cancer Epidemiol.*, 2010; 34: 618-625.
2. Andreev DN, Maev IV, Dicheva DT. Efficiency of the inclusion of rebamipide in the eradication therapy for *Helicobacter pylori* infection: meta-analysis of randomized controlled studies. *J Clin Med.*, 2019; 8:1498-1507.
3. Ansari S, Yamaoka Y. Current understanding and management of *Helicobacter pylori* infection: an updated appraisal. *F1000Research*, 2018; 7(F1000 Faculty Rev): 721: 1-10.
4. Bektas H, Ceylan S, Demirbas N, Alpay-Karaoglu S, Sokmen BB. Antimicrobial and antiurease activities of newly synthesized morphline derivatives containing an azole nucleus. *Med Chem Res.*, 2013; 22(8): 3629-3639.
5. Chey WD, Leonardi GI, Howden CW, Moss SF. AGC Clinical Guideline: treatment of *Helicobacter pylori* infection. *Am J Gastroenterol.*, 2017; 112(2): 212-238.
6. Crowe SE. *Helicobacter pylori* infection. *N Engl J Med.*, 2019; 380(12): 1158-1165.
7. Dawood KM, Farghaly TA, Thia diazole inhibitors: a patent review. *ExpOpinTher Pat.*, 2017; 27(4): 477-505.
8. Diaba F, Montiel JA, Serban G, Bonjoch J. Synthesis of normorphans through an efficient intramolecular carbamoylation of ketones. *Org Lett.*, 2015; 17(15): 3860-3863.
9. Foroumadi A, Sorkhi M, Moshafi MH, Safavi M, Rineh A, Siavoshi F, Shafiee A. 2-Substituted-5-nitroheterocycles: in vitro anti-Helicobacter pylori activity and structure-activity relationship study. *Med. Chem.*, 2009; 5(6): 529-534.
10. Haider S, Alam MS, Hamid H, 1,3,4-Thia diazoles: a potent multi targeted pharmaceutical scaffold. *Eur J Med Chem.*, 2015; 92: 156-177.
11. Hooi KY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Mallerheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JYI, Kaplan GG, Ng SC. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology*, 2017; 153(2):420-429.
12. Joule JA. Advances in heterocyclic chemistry: heterocyclic chemistry in the 21st century – a tribute to Alan Katritzky, 1st ed., Academic Press Elsevier, Cambridge, 2016, Volume 119: 81-106.
13. Juszczak M, Matysiak J, Brzana W, Niewiadomy A, Rzeski W. Evaluation of antiproliferative activity of 2-(monohalogenophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. *Argneim Forsch Drug Res.*, 2008; 58(7): 353-357.
14. Khan I, Ali S, Hameed S, Rama NH, Hussain MT, Wadood A, Uddin R, Ul-Haq Z, Khan A, Ali S, Choudhary MI. Synthesis, antioxidant activities and urease inhibition of some new 1,2,4-triazole and 1,3,4-thiadiazole derivatives. *Eur J Med Chem.*, 2010; 45(11): 5200-5207.
15. Korns G. Comprehensive heterocyclic chemistry II. Elsevier, Oxford, 1996, Volume 4: 379-408.
16. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev.*, 2006; 19(3): 449-490.
17. Li Y, Geng J, Liu Y, Yu S, Zhao G. Thia diazole – a promising structure in Medicinal Chemistry. *Chem Med Chem.*, 2013; 8(1): 27-41.
18. Matysiak J. Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives. *Chem Pharm Bull.*, 2006; 54(7): 988-991.
19. Mihai C, Mihai BM, Dranga M, Cardoneanu A, Cijevschi Prelipcean C, Lactobacillus reuteri – an alternative in the first-line of *Helicobacter pylori* eradication. *Farmacia*, 2019; 67(5): 871-876.
20. Modolo LV, de Souza AX, Horta LP, Araujo DP, de Fatima A. An overview on the potential of natural products as ureases inhibitors: A review. *J Adv Res.*, 2015; 6(1):35-44.
21. Safavi M, Sabourian R, Foroumadi A. Treatment of *Helicobacter pylori* infection: current and future insights. *World J Clin Cases*, 2016; 4(1): 5-19.
22. Saleem M, Rafiq M, Hanif M, Rama NH, Seo SY, Lee KH. Synthesis, urease and acetylcholine esterase inhibition activities of some 1,4-disubstituted thi semicarbazides and their 2,5-disubstituted thiadiazoles. *Bull Korean Chem Soc.*, 2012; 33(8): 2741-2747.
23. Schmidt HMA, Andres S, Kaakoush NO, Engrandi L, Eriksson L, Goh KL, Fock KM, Hilmi I, Forman D, Mitchell H. The prevalence of the duodenal ulcer promoting gene (dupA) in *Helicobacter pylori* isolates varies by ethnic group and is not universally associated with disease development: a case-control study. *Gut Pathog.*, 2009; 1(1):5: 1-8.
24. Seniff-Ribeiro A, Echevarria A, Silva EF, Franco CRC, Veiga SS, Oliveira MBM. Cytotoxic effect of a new 1,3,4-thiadiazolium mesioniconic (MI-D) on cell lines of human melanoma. *Br J Cancer*, 2004; 91(2): 297-304.
25. Serban G, 5-Arylamino-1,3,4-thiadiazol-2-yl acetic acid esters as intermediates for the synthesis of new bis heterocyclic compounds. *Farmacia*, 2015; 63(1): 146-149.
26. Serban G, Abe H, Takeuchi Y, Harayama T, A new approach to the benzopyridoxepine core by metal mediated intramolecular biaryl ether formation. *Heterocycles*, 2008; 75: 2949-2958.
27. Serban G. Future prospects in the treatment of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasis. *Molecules*, 2019; 24(8): 1557-1578.
28. Serban G, Shigeta Y, Nishioka H, Abe H, Takeuchi Y, Harayama T. Studies toward the synthesis of todlaquinoline by intramolecular cyclization. *Heterocycles*, 2007; 71: 1623-1630.
29. Serban G, Stanasel O, Serban E, Bota S, 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising
antimicrobial agents. Drug Des Devel Ther., 2018; 12:1545-1566.
30. Serban G, 2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. Acta Pharm., 2020; 70(3):259-290.
31. Serban G. Synthetic compounds with 2-amino-1,3,4-thiadiazole moiety against viral infections. Molecules, 2020; 25(4): 942-963.
32. Shukla PK, Verma A, Mishra P, New perspective in agricultural and human health, Bharti Publication, New Delhi, 2017, 100-126.
33. Song M, Ang TL, Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol., 2014; 20(6): 1517-1528.
34. Suzuki H, Nishizawa T, Hibi T, Helicobacter pylori eradication therapy. Future Microbiol., 2010; 5(4): 639-648.
35. Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T, Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol., 2019; 25(16):1907-1912.
36. Tafti AF, Akbarzadeh T, Saniee P, Siavoshi F, Shafiee A, Foroumadi A, Synthesis and anti-Helicobacter pylori activity of (4-nitro-1-imidazolymethyl)-1,2,4-triazoles, 1,3,4-thiadiazoles, and 1,3,4-oxadiazoles. Turk J Chem., 2011; 35(2): 307-316.
37. Takashima K, Hayakawa D, Gouda H, Toyooka N, Formal syntheses of (-)-Lepadiformines A and (-)-Fasicularin. J Org Chem., 2019; 84(9): 5222-5229.
38. Uotani T, Graham DY, Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med., 2015; 3(1): 9: 1-7.
39. Van den Broek SBAMW, Meeuwsen SA, van Delft FL, Rutjes FPTJ, Metathesis in natural product synthesis: strategies, substrates and catalysts, Wiley-VCH, Weinheim, 2010, 45-85.
40. van Duynhoven YTHP, de Jonge R, Transmission of Helicobacter pylori: a role for food?. Bull World Health Org., 2001; 79(5): 455-460.
41. Wen S, Moss SF, Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett., 2009; 282(1): 1-8.
42. Wong WM, Gu Q, Chu KM, Yee YK, Fung FMY, Tong TSM., Chan AOO., Lai KC, Chan CK, Wong BCY, Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther., 2006; 23(3): 421-427.
43. Yoosefi an M, Chermahini ZJ, Raissi H, Mola A, Saleghi M, A theoretical study on the structure of 2-amino-1,3,4-thiadiazole and its 5-substituted derivatives in the gas phase, water, THF and DMSO solutions. J Mol Liq., 2015; 203: 137-142.
44. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH, Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment PharmacolTher., 2018; 47(7): 868-876.
45. Zhu HL, Liu YW, Tang ZM, Yin FJ, Liu WW, Cao ZL, Bao J, Li M, Qin LY, Shi DH, Synthesis, crystal structures and biological activity of zinc(II) complexes derived from 2-amino-1,3,4-thiadiazole derivatives. Inorg Nano-Metal Chem., 2016; 47(1): 78-81.